首页|肿瘤浸润淋巴细胞治疗胃癌的研究进展

肿瘤浸润淋巴细胞治疗胃癌的研究进展

扫码查看
胃癌是全球范围内常见的恶性肿瘤之一,其发病率和死亡率均较高。传统的胃癌治疗方法包括手术、化疗和放疗等在治疗效果上存在一定的局限性,尤其是对于晚期或转移性胃癌患者,治疗效果往往不佳。肿瘤浸润淋巴细胞(TIL)疗法是一种新型细胞免疫疗法,通过利用患者自身的免疫细胞来攻击肿瘤细胞,展现出了较强的特异性和安全性。因此,深入探究和明确TIL治疗胃癌的机制与疗效具有重要的基础研究意义和临床应用价值,本文将综述TIL治疗胃癌的研究进展,并对其进行述评。
Research progress on tumor infiltrating lymphocytes for the treatment of gastric cancer
Gastric cancer is one of the most common malignant tumors in the world,with a high in-cidence rate and mortality.The traditional treatment methods for gastric cancer,including surgery,chemo-therapy,and radiation therapy,have certain limitations in terms of treatment effectiveness,especially for patients with advanced or metastatic gastric cancer.Tumor-infiltrating lymphocyte(TIL)therapy is a novel cellular immunotherapy that utilizes the patient's own immune cells to attack tumor cells,demonstrating strong specificity and safety.Therefore,in-depth exploration and clarification of the mechanism and effica-cy of TIL treatment for gastric cancer have important basic research significance and clinical application val-ue.This article will review the research progress of TIL treatment for gastric cancer and provide a commen-tary on it.

Tumor infiltrating lymphocytesGastric cancer

江蜜、陈锦皇、舒晓刚

展开 >

华中科技大学同济医学院附属协和医院胃肠外科,武汉 430022

华中科技大学同济医学院附属协和医院急诊外科,武汉 430022

肿瘤浸润淋巴细胞 胃癌

2024

中华实验外科杂志
中华医学会

中华实验外科杂志

CSTPCD
影响因子:0.759
ISSN:1001-9030
年,卷(期):2024.41(12)